Polyplus-transfection® SA is the leading biotechnology company that supports Gene and Cell therapy, biologics manufacturing and life science research with Innovative nucleic acid transfection solutions.
Polyplus-transfection SA holds a strong portfolio of patents and patent applications. Our Research and Development focuses on the development of innovative and efficient solutions for the delivery of nucleic acids in research, bioproduction and therapeutics
jetPRIME®
- High DNA transfection efficiency
- Low amounts of nucleic acid
- Superior cell viability
- ONE reagent for DNA and/or siRNA transfections
- Cost-effective
PEIpro®
- Optimized PEI-based transfection reagent for scalable virus production
- Superior viral titers compared to other commercial PEIs and Calcium Phosphate
- Suitable for Process Development of large-scale virus production
- Reliable and secure supply
in vivo-jetPEI®
- Polyvalent: in vivo delivery of DNA, si/sh/miRNA in any animal model
- Easy to use: two-step protocol
- Renowned: Most advanced in vivo transfection technology with over 700 peer-reviewed publications
- Successful: Used from fundamental research to Human clinical trials
Brochures
In Vivo & in Vitro Transfection Studies
Gene expression is the process by which genetic information stored into a nucleic acid sequence is converted into a polypeptide chain, the building blocks of proteins. This process is routinely exploited in the lab to study the function of a protein of interest and or its role in a signaling pathway. For this, scientist engineer plasmid DNA or mRNA coding for a gene of interest that is transfected into mammalian cells to force transient production of the protein of interest.
RNA interference (RNAi), the process of gene regulation in mammalian cells, is routinely used by scientists to investigate the role of endogenous genes by transiently silencing their expression (siRNA) or by regulating expression of one or several genes (miRNA). Expression of ectopically expressed proteins can also be modulated by co-transfecting a plasmid DNA coding for an ectopic protein along with the oligonucleotide targeted against the gene of interest.
jetPRIME® INTERFERin®CRISPR/Cas9 genome editing is a technology that allows scientist to modify the genome of cell at a specific locus. CRISPR/Cas9 is a two-component system composed of a guide RNA molecule that drives the Cas9 endonuclease to cut at a specific sequence within the genome. There are three methods to transfect guide RNA and express Cas9 protein in mammalian cells: DNA-, RNA- or ribonucleoprotein-based delivery. Each system has their own pros and cons in terms of easiness of use, genome editing efficiency and off-target effects.
jetOPTIMUS® jetMESSENGER® jetCRISPR®Protein delivery is a great alternative to gene expression for the study of protein function. Instead of transfecting DNA or mRNA encoding for a protein of interest, the protein itself is directly transfected into mammalian cells. Protein delivery offers a panel of possibilities in live cells, including protein interference with blocking antibodies, live immunolabelling, intracellular trafficking and protein-protein interaction studies.
jetCRISPR® PULSinEach primary cell type has distinct properties that allows them to fulfill their role in the body. Once isolated from their tissue of origin, some primary cell types are harder to culture because they are more fragile and have distinct morphologies. These primary cell types require the development of cell specific transfection reagents that efficiently deliver nucleic acids and respect cell morphology.
jetPEI®-Macrophage jetPEI®-HepatocyteProduction of recombinant viral particles is dependent on transfection of 2-4 plasmid DNA into host adherent or suspension mammalian cells such as HEK-293 cells and derivatives. The produced recombinant viral particles are then used as vehicles to carry the corrective gene into cells ex vivo (cell therapy) or directly in vivo (gene therapy). Production of therapeutic viral vectors is dependent on a transfection method that can achieve reliable viral vector production, high infectious titer yields, and direct scalability from process development up to large-scale clinical-grade manufacturing.
FectoVIR®-AAV PEIpro®-GMP PEIpro® PEIpro®-HQRecombinant protein production for therapy and diagnostic applications is mainly achieved in CHO and HEK-293 cell lines adapted for growth in suspension. CHO and HEK-293 cells grown in suspension are ideal to maximize protein production yields, while improving overall production process by culturing them in chemically defined serum-free media (costs, downstream purification steps, reproducibility…). Several CHO and HEK-293 cell lines have been engineered to further improve yield of production, notably by enabling them to grow at higher density in defined cell culture media. With these modified properties, TGE in suspension CHO and HEK-293 cells lines relies on a transfection reagent that is efficient at different cell densities and in different synthetic media.
FectoPRO® FectoCHO® Expression SystemIn vivo delivery of nucleic acids into animal models is essential for basic research as well as for medical applications such as gene therapy. Depending on the nucleic acid delivered, gene expression or gene silencing can be mediated in various tissues. Different routes of administration can be used and largely determine the targeted organ in which the nucleic acid will be expressed.
in vivo-jetPEI® in vivo-jetPEI®-PC GMP in vivo-jetPEI®in vivo mRNA delivery reagent is specifically developed to deliver mRNA in various animal models. Depending on the chosen route of administration, mRNA can be efficiently delivered to different organs in various animal models. Non-viral mRNA transfection is a promising method specifically for vaccination and in anti-cancer therapy.
in vivo-jetRNA®Non-viral in vivo delivery is a safe method for delivery of nucleic acids in different organs of various animal models. Certain cell types are less permissive to in vivo transfection and require the development of specific transfection reagents to improve nucleic acid targeting efficiency.
in vivo-jetPEI®-Man in vivo-jetPEI®-Gal jetSI 10 mM